| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 83 | 2026 | 3651 | 5.310 |
Why?
|
| Contrast Media | 53 | 2026 | 1096 | 4.790 |
Why?
|
| Prostatic Neoplasms | 37 | 2025 | 1798 | 3.490 |
Why?
|
| Image Enhancement | 20 | 2021 | 565 | 1.900 |
Why?
|
| Image Processing, Computer-Assisted | 17 | 2026 | 1323 | 1.500 |
Why?
|
| Algorithms | 13 | 2025 | 2014 | 1.420 |
Why?
|
| Gadolinium DTPA | 16 | 2017 | 255 | 1.390 |
Why?
|
| Models, Theoretical | 9 | 2018 | 503 | 1.130 |
Why?
|
| Image Interpretation, Computer-Assisted | 13 | 2019 | 703 | 1.040 |
Why?
|
| Ultrasonic Therapy | 6 | 2012 | 44 | 0.950 |
Why?
|
| Prostate | 11 | 2023 | 423 | 0.950 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 12 | 2023 | 301 | 0.940 |
Why?
|
| Signal-To-Noise Ratio | 4 | 2021 | 115 | 0.930 |
Why?
|
| Mammary Glands, Animal | 8 | 2020 | 81 | 0.930 |
Why?
|
| Mammary Neoplasms, Experimental | 7 | 2015 | 133 | 0.850 |
Why?
|
| Arteries | 4 | 2021 | 181 | 0.840 |
Why?
|
| Ultrasonics | 7 | 2012 | 38 | 0.790 |
Why?
|
| Breast Neoplasms | 19 | 2026 | 3147 | 0.790 |
Why?
|
| Computer Simulation | 11 | 2021 | 1158 | 0.790 |
Why?
|
| Mammary Neoplasms, Animal | 4 | 2020 | 58 | 0.710 |
Why?
|
| Models, Biological | 14 | 2025 | 1815 | 0.690 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 5 | 2015 | 126 | 0.690 |
Why?
|
| Muscle, Skeletal | 7 | 2020 | 483 | 0.660 |
Why?
|
| Reproducibility of Results | 22 | 2021 | 2883 | 0.660 |
Why?
|
| Carcinoma, Ductal, Breast | 4 | 2014 | 166 | 0.630 |
Why?
|
| Breast | 8 | 2017 | 297 | 0.550 |
Why?
|
| Phantoms, Imaging | 5 | 2015 | 491 | 0.530 |
Why?
|
| Carcinoma in Situ | 2 | 2015 | 53 | 0.530 |
Why?
|
| Organometallic Compounds | 4 | 2021 | 148 | 0.530 |
Why?
|
| Animals | 51 | 2025 | 28945 | 0.500 |
Why?
|
| Sensitivity and Specificity | 16 | 2023 | 2040 | 0.490 |
Why?
|
| Rats | 18 | 2017 | 4154 | 0.490 |
Why?
|
| Male | 47 | 2025 | 45870 | 0.470 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2020 | 277 | 0.450 |
Why?
|
| Humans | 74 | 2026 | 96127 | 0.400 |
Why?
|
| Hyperthermia, Induced | 5 | 2012 | 75 | 0.400 |
Why?
|
| Neoplasms, Experimental | 2 | 2005 | 271 | 0.380 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2020 | 630 | 0.380 |
Why?
|
| Blood-Brain Barrier | 3 | 2025 | 80 | 0.380 |
Why?
|
| Biomimetic Materials | 1 | 2012 | 26 | 0.360 |
Why?
|
| Neoplasm Transplantation | 6 | 2010 | 413 | 0.350 |
Why?
|
| Abdominal Abscess | 1 | 2011 | 23 | 0.350 |
Why?
|
| Mice | 28 | 2025 | 12562 | 0.350 |
Why?
|
| Tumor Hypoxia | 2 | 2022 | 43 | 0.350 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 1 | 2012 | 48 | 0.350 |
Why?
|
| Neoadjuvant Therapy | 2 | 2026 | 444 | 0.340 |
Why?
|
| Subtraction Technique | 3 | 2009 | 130 | 0.340 |
Why?
|
| Meglumine | 3 | 2021 | 38 | 0.330 |
Why?
|
| Middle Aged | 35 | 2026 | 28363 | 0.320 |
Why?
|
| Camellia sinensis | 1 | 2009 | 6 | 0.310 |
Why?
|
| Angiogenesis Modulating Agents | 1 | 2009 | 4 | 0.310 |
Why?
|
| Female | 44 | 2026 | 50063 | 0.310 |
Why?
|
| Peripheral Arterial Disease | 2 | 2021 | 102 | 0.300 |
Why?
|
| Neovascularization, Pathologic | 5 | 2015 | 355 | 0.290 |
Why?
|
| Fluorine | 2 | 2005 | 17 | 0.290 |
Why?
|
| Computed Tomography Angiography | 2 | 2021 | 166 | 0.290 |
Why?
|
| Fourier Analysis | 5 | 2016 | 128 | 0.280 |
Why?
|
| Diet, High-Fat | 2 | 2020 | 135 | 0.280 |
Why?
|
| Plant Extracts | 1 | 2009 | 248 | 0.270 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2025 | 590 | 0.260 |
Why?
|
| Laser Therapy | 2 | 2018 | 151 | 0.250 |
Why?
|
| Adipose Tissue | 2 | 2006 | 270 | 0.250 |
Why?
|
| Carcinogenesis | 2 | 2020 | 237 | 0.250 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2020 | 184 | 0.250 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2006 | 14 | 0.240 |
Why?
|
| Aged | 22 | 2026 | 20964 | 0.240 |
Why?
|
| Fluorocarbons | 1 | 2005 | 72 | 0.230 |
Why?
|
| Ultrasonography | 4 | 2014 | 744 | 0.230 |
Why?
|
| Pilot Projects | 10 | 2021 | 938 | 0.230 |
Why?
|
| Echo-Planar Imaging | 5 | 2008 | 52 | 0.220 |
Why?
|
| Misonidazole | 2 | 2022 | 18 | 0.220 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2002 | 325 | 0.220 |
Why?
|
| Prostatectomy | 6 | 2023 | 480 | 0.220 |
Why?
|
| Body Water | 3 | 2004 | 35 | 0.220 |
Why?
|
| Gadolinium | 2 | 2018 | 106 | 0.220 |
Why?
|
| Muscle Neoplasms | 1 | 2004 | 17 | 0.210 |
Why?
|
| Retrospective Studies | 12 | 2026 | 10286 | 0.210 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2023 | 149 | 0.210 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2023 | 465 | 0.200 |
Why?
|
| Myocardium | 1 | 2006 | 596 | 0.200 |
Why?
|
| Thorax | 2 | 2000 | 80 | 0.200 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2024 | 204 | 0.200 |
Why?
|
| Neoplasm Invasiveness | 5 | 2020 | 590 | 0.200 |
Why?
|
| Mice, Transgenic | 7 | 2018 | 1645 | 0.190 |
Why?
|
| Carbon Dioxide | 2 | 2002 | 212 | 0.190 |
Why?
|
| Oxygen | 4 | 2021 | 788 | 0.190 |
Why?
|
| Water | 4 | 2009 | 307 | 0.180 |
Why?
|
| Feasibility Studies | 7 | 2020 | 819 | 0.180 |
Why?
|
| Adult | 21 | 2026 | 28718 | 0.180 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2023 | 111 | 0.180 |
Why?
|
| Receptor, ErbB-2 | 1 | 2023 | 280 | 0.180 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2023 | 176 | 0.170 |
Why?
|
| Neoplasms | 7 | 2020 | 3250 | 0.170 |
Why?
|
| Rats, Inbred F344 | 4 | 2005 | 165 | 0.170 |
Why?
|
| Cognition | 1 | 2025 | 635 | 0.170 |
Why?
|
| Leg | 1 | 2021 | 143 | 0.160 |
Why?
|
| Acoustics | 2 | 1997 | 51 | 0.160 |
Why?
|
| Time Factors | 8 | 2025 | 5585 | 0.160 |
Why?
|
| Neoplasm Grading | 4 | 2023 | 404 | 0.160 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2020 | 111 | 0.150 |
Why?
|
| Lower Extremity | 1 | 2020 | 98 | 0.150 |
Why?
|
| Electromagnetic Fields | 1 | 1999 | 28 | 0.150 |
Why?
|
| Ischemia | 1 | 2021 | 257 | 0.150 |
Why?
|
| Microvessels | 2 | 2009 | 74 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2022 | 2781 | 0.140 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2018 | 34 | 0.140 |
Why?
|
| Disease Models, Animal | 8 | 2020 | 2551 | 0.140 |
Why?
|
| Dietary Sugars | 1 | 2018 | 8 | 0.140 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 1 | 2018 | 12 | 0.140 |
Why?
|
| Diet, Fat-Restricted | 1 | 2018 | 30 | 0.140 |
Why?
|
| Prostatic Hyperplasia | 1 | 2019 | 97 | 0.140 |
Why?
|
| Information Storage and Retrieval | 2 | 2010 | 127 | 0.140 |
Why?
|
| Hindlimb | 3 | 2010 | 97 | 0.140 |
Why?
|
| Brain Neoplasms | 2 | 2014 | 855 | 0.140 |
Why?
|
| Androgen Antagonists | 3 | 2023 | 144 | 0.140 |
Why?
|
| Feeding Behavior | 1 | 2020 | 338 | 0.130 |
Why?
|
| Pulse Wave Analysis | 1 | 2017 | 10 | 0.130 |
Why?
|
| Prospective Studies | 6 | 2018 | 4671 | 0.130 |
Why?
|
| Therapy, Computer-Assisted | 2 | 1995 | 19 | 0.130 |
Why?
|
| Wrist | 1 | 2017 | 29 | 0.130 |
Why?
|
| Oxides | 3 | 2002 | 44 | 0.130 |
Why?
|
| Fatty Acids | 1 | 2018 | 153 | 0.130 |
Why?
|
| Dietary Fats | 1 | 2017 | 137 | 0.130 |
Why?
|
| Brain | 3 | 2025 | 2482 | 0.120 |
Why?
|
| Iron | 3 | 2002 | 179 | 0.120 |
Why?
|
| Immunohistochemistry | 4 | 2016 | 1829 | 0.120 |
Why?
|
| Durapatite | 1 | 2015 | 36 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 1105 | 0.120 |
Why?
|
| Biopsy | 6 | 2019 | 1220 | 0.120 |
Why?
|
| Diagnosis, Differential | 5 | 2019 | 1619 | 0.120 |
Why?
|
| Observer Variation | 2 | 2021 | 626 | 0.120 |
Why?
|
| ROC Curve | 5 | 2018 | 797 | 0.110 |
Why?
|
| Evaluation Studies as Topic | 3 | 2006 | 271 | 0.110 |
Why?
|
| Calcium Oxalate | 1 | 2015 | 188 | 0.110 |
Why?
|
| Kinetics | 5 | 2023 | 1562 | 0.110 |
Why?
|
| Metal Nanoparticles | 1 | 2014 | 34 | 0.110 |
Why?
|
| Temperature | 4 | 1999 | 426 | 0.110 |
Why?
|
| Gold | 1 | 2014 | 44 | 0.110 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 114 | 0.100 |
Why?
|
| Reference Values | 2 | 2015 | 675 | 0.100 |
Why?
|
| Doxorubicin | 1 | 2014 | 304 | 0.100 |
Why?
|
| Crohn Disease | 2 | 2011 | 806 | 0.100 |
Why?
|
| Oncolytic Virotherapy | 1 | 2013 | 43 | 0.100 |
Why?
|
| Thermometers | 3 | 1999 | 6 | 0.100 |
Why?
|
| Models, Anatomic | 2 | 1998 | 93 | 0.100 |
Why?
|
| Manganese Compounds | 1 | 2012 | 5 | 0.100 |
Why?
|
| Neural Stem Cells | 1 | 2013 | 68 | 0.100 |
Why?
|
| Cell Line, Tumor | 4 | 2023 | 2794 | 0.100 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2013 | 82 | 0.100 |
Why?
|
| Disease Progression | 2 | 2014 | 1568 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2023 | 285 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 3 | 2004 | 1054 | 0.090 |
Why?
|
| Metabolic Clearance Rate | 4 | 2015 | 119 | 0.090 |
Why?
|
| Transducers | 3 | 1997 | 45 | 0.090 |
Why?
|
| Niacinamide | 1 | 2012 | 102 | 0.090 |
Why?
|
| Chlorides | 1 | 2012 | 108 | 0.090 |
Why?
|
| Phenylurea Compounds | 1 | 2012 | 99 | 0.090 |
Why?
|
| Stem Cell Transplantation | 1 | 2013 | 192 | 0.090 |
Why?
|
| Scattering, Radiation | 1 | 1992 | 122 | 0.090 |
Why?
|
| Glioma | 1 | 2014 | 321 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2015 | 565 | 0.090 |
Why?
|
| Tissue Culture Techniques | 1 | 2011 | 82 | 0.090 |
Why?
|
| Ascites | 1 | 2011 | 58 | 0.090 |
Why?
|
| Proteomics | 2 | 2023 | 269 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 311 | 0.090 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 232 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 305 | 0.080 |
Why?
|
| Blood Vessels | 1 | 2011 | 92 | 0.080 |
Why?
|
| Diffusion | 3 | 2013 | 95 | 0.080 |
Why?
|
| Glioblastoma | 1 | 2013 | 286 | 0.080 |
Why?
|
| X-Ray Microtomography | 1 | 2011 | 102 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 777 | 0.080 |
Why?
|
| Swine | 1 | 2012 | 618 | 0.080 |
Why?
|
| Mice, Knockout | 1 | 2015 | 2163 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 475 | 0.080 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 299 | 0.080 |
Why?
|
| Injections | 3 | 2017 | 126 | 0.080 |
Why?
|
| Macrophages | 2 | 2023 | 626 | 0.080 |
Why?
|
| Pregnancy | 3 | 2025 | 3240 | 0.080 |
Why?
|
| Positron-Emission Tomography | 2 | 2022 | 354 | 0.080 |
Why?
|
| Electron Spin Resonance Spectroscopy | 2 | 2022 | 329 | 0.080 |
Why?
|
| Glucose | 1 | 2012 | 701 | 0.080 |
Why?
|
| Radiation Dosage | 2 | 2021 | 236 | 0.080 |
Why?
|
| Extracellular Space | 1 | 2009 | 90 | 0.080 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2009 | 7 | 0.070 |
Why?
|
| Intestine, Small | 1 | 2011 | 310 | 0.070 |
Why?
|
| Perfusion Imaging | 1 | 2009 | 52 | 0.070 |
Why?
|
| Radiotherapy, Conformal | 1 | 2009 | 89 | 0.070 |
Why?
|
| Breast Diseases | 2 | 2011 | 101 | 0.070 |
Why?
|
| Insulin-Secreting Cells | 1 | 2012 | 442 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 7232 | 0.070 |
Why?
|
| Artifacts | 2 | 2015 | 252 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 611 | 0.070 |
Why?
|
| Leiomyoma | 1 | 2012 | 211 | 0.070 |
Why?
|
| Mice, Nude | 4 | 2013 | 842 | 0.070 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2006 | 205 | 0.070 |
Why?
|
| Uterine Neoplasms | 1 | 2012 | 278 | 0.070 |
Why?
|
| Tumor Burden | 2 | 2020 | 323 | 0.070 |
Why?
|
| Ferrosoferric Oxide | 3 | 2002 | 19 | 0.070 |
Why?
|
| Magnetite Nanoparticles | 3 | 2002 | 27 | 0.070 |
Why?
|
| Dextrans | 3 | 2002 | 78 | 0.070 |
Why?
|
| Equipment Design | 2 | 2006 | 427 | 0.070 |
Why?
|
| Colitis | 1 | 2010 | 262 | 0.060 |
Why?
|
| Protons | 2 | 2008 | 104 | 0.060 |
Why?
|
| Genetic Therapy | 1 | 2009 | 382 | 0.060 |
Why?
|
| Materials Testing | 1 | 2006 | 94 | 0.060 |
Why?
|
| Hypoxia | 2 | 2022 | 682 | 0.060 |
Why?
|
| Emulsions | 1 | 2005 | 19 | 0.060 |
Why?
|
| Hot Temperature | 2 | 2014 | 217 | 0.060 |
Why?
|
| Germ-Free Life | 1 | 2025 | 83 | 0.060 |
Why?
|
| Carcinoma | 1 | 2008 | 449 | 0.060 |
Why?
|
| Necrosis | 2 | 1996 | 210 | 0.060 |
Why?
|
| Area Under Curve | 3 | 2011 | 340 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2026 | 392 | 0.060 |
Why?
|
| Spin Labels | 2 | 2015 | 107 | 0.050 |
Why?
|
| Biophysical Phenomena | 2 | 1995 | 125 | 0.050 |
Why?
|
| Biophysics | 2 | 1995 | 157 | 0.050 |
Why?
|
| Molecular Weight | 1 | 2004 | 333 | 0.050 |
Why?
|
| Lactates | 1 | 2023 | 39 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 1069 | 0.050 |
Why?
|
| Lead | 1 | 2023 | 32 | 0.050 |
Why?
|
| Aging | 1 | 2008 | 766 | 0.050 |
Why?
|
| General Surgery | 2 | 1996 | 255 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 98 | 0.050 |
Why?
|
| Phagocytosis | 1 | 2023 | 116 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2023 | 108 | 0.050 |
Why?
|
| Radiography | 3 | 2012 | 826 | 0.050 |
Why?
|
| Brain Chemistry | 1 | 2002 | 120 | 0.050 |
Why?
|
| Antigens, Polyomavirus Transforming | 2 | 2015 | 48 | 0.050 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2009 | 647 | 0.050 |
Why?
|
| Wnt Signaling Pathway | 1 | 2023 | 103 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2025 | 3490 | 0.050 |
Why?
|
| Models, Statistical | 3 | 2011 | 594 | 0.050 |
Why?
|
| Motion | 1 | 2022 | 99 | 0.050 |
Why?
|
| beta Catenin | 1 | 2023 | 267 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2023 | 404 | 0.050 |
Why?
|
| Rhabdomyosarcoma | 1 | 2002 | 44 | 0.050 |
Why?
|
| Prognosis | 2 | 2026 | 4033 | 0.040 |
Why?
|
| Cell Hypoxia | 1 | 2022 | 188 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2023 | 367 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2023 | 305 | 0.040 |
Why?
|
| Bacteria | 1 | 2025 | 517 | 0.040 |
Why?
|
| Tibial Arteries | 1 | 2021 | 5 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 204 | 0.040 |
Why?
|
| Fibula | 1 | 2021 | 32 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2009 | 1665 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2023 | 9173 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2020 | 372 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 104 | 0.040 |
Why?
|
| Regional Blood Flow | 1 | 2020 | 198 | 0.040 |
Why?
|
| Young Adult | 3 | 2017 | 7025 | 0.040 |
Why?
|
| Indicator Dilution Techniques | 1 | 2019 | 9 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 379 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 1973 | 0.040 |
Why?
|
| Cytological Techniques | 1 | 1999 | 31 | 0.040 |
Why?
|
| Microwaves | 1 | 1999 | 32 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 1999 | 202 | 0.040 |
Why?
|
| Ultrasonography, Interventional | 1 | 1999 | 125 | 0.040 |
Why?
|
| Fructose | 1 | 2018 | 36 | 0.030 |
Why?
|
| Image-Guided Biopsy | 1 | 2018 | 81 | 0.030 |
Why?
|
| Random Allocation | 1 | 2018 | 327 | 0.030 |
Why?
|
| Weaning | 1 | 2017 | 26 | 0.030 |
Why?
|
| Radial Artery | 1 | 2017 | 37 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 194 | 0.030 |
Why?
|
| Adiposity | 1 | 2017 | 80 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2001 | 1103 | 0.030 |
Why?
|
| Pressure | 1 | 2017 | 175 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2023 | 2614 | 0.030 |
Why?
|
| Time | 1 | 2016 | 79 | 0.030 |
Why?
|
| Thermal Conductivity | 1 | 1996 | 3 | 0.030 |
Why?
|
| Sonication | 1 | 1996 | 4 | 0.030 |
Why?
|
| Mathematics | 1 | 1996 | 191 | 0.030 |
Why?
|
| Auditory Perception | 1 | 1997 | 105 | 0.030 |
Why?
|
| Simian virus 40 | 1 | 2015 | 36 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2026 | 2642 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 2463 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2002 | 1215 | 0.030 |
Why?
|
| Edema | 1 | 2014 | 73 | 0.030 |
Why?
|
| Color | 1 | 2014 | 87 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2014 | 124 | 0.030 |
Why?
|
| Mammography | 1 | 2017 | 475 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 1999 | 2943 | 0.030 |
Why?
|
| Rabbits | 1 | 2014 | 639 | 0.020 |
Why?
|
| Perfusion | 1 | 2014 | 266 | 0.020 |
Why?
|
| Streptozocin | 1 | 2012 | 56 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2023 | 3586 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2013 | 342 | 0.020 |
Why?
|
| Fats | 1 | 2011 | 12 | 0.020 |
Why?
|
| Mastectomy, Segmental | 1 | 2012 | 108 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2012 | 318 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 535 | 0.020 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2012 | 201 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2019 | 2480 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2011 | 48 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 377 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 1267 | 0.020 |
Why?
|
| Fluorescence | 1 | 2011 | 106 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 238 | 0.020 |
Why?
|
| Intestines | 1 | 2013 | 431 | 0.020 |
Why?
|
| Angiography | 1 | 2011 | 209 | 0.020 |
Why?
|
| Ileum | 1 | 2011 | 169 | 0.020 |
Why?
|
| Biological Transport | 1 | 2010 | 412 | 0.020 |
Why?
|
| Extremities | 1 | 2011 | 179 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 2081 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 599 | 0.020 |
Why?
|
| Deuterium | 1 | 2008 | 35 | 0.020 |
Why?
|
| Spectrophotometry | 1 | 2008 | 108 | 0.020 |
Why?
|
| Microscopy | 1 | 2008 | 91 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2009 | 444 | 0.020 |
Why?
|
| Dogs | 2 | 1999 | 719 | 0.020 |
Why?
|
| Endoscopy | 1 | 2011 | 374 | 0.020 |
Why?
|
| Radiology | 1 | 2008 | 206 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 1773 | 0.010 |
Why?
|
| Inflammation | 1 | 2011 | 1068 | 0.010 |
Why?
|
| Kidney | 2 | 1999 | 1156 | 0.010 |
Why?
|
| Ribs | 1 | 1999 | 50 | 0.010 |
Why?
|
| Lung | 1 | 1999 | 1382 | 0.010 |
Why?
|